心力衰竭患者血浆可溶性晚期糖基化终末产物受体(sRAGE)变化与心功能的关系

doi:10.3969/j.issn.1006-7795.2014.06.023

首都医科大学学报 ›› 2014, Vol. 35 ›› Issue (6): 805-808.doi: 10.3969/j.issn.1006-7795.2014.06.023

心力衰竭患者血浆可溶性晚期糖基化终末产物受体(sRAGE)变化与心功能的关系

郭新颖¹, 郭彩霞², 杜凤和², 陈步星²

1. 首都医科大学附属北京同仁医院心血管中心, 北京 100730;
2. 首都医科大学附属北京天坛医院心内科, 北京 100050

收稿日期:2014-03-05 发布日期:2014-12-15
通讯作者: 郭彩霞 E-mail:cxgbb@163.com
基金资助:
国家自然科学基金(81370313),北京市科技新星计划基金(2010B050)

Relationship between plasma sRAGE and heart function in patients with heart failure

Guo Xinying¹, Guo Caixia², Du Fenghe², Chen Buxing²

1. Cardiovascular Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China;
2. Department of Cardiology Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China

Received:2014-03-05 Published:2014-12-15
Supported by:
This study was supported by National Natural Science Foundation of China(81370313), Sci-tech"New Star" Program of Beijing(2010B050).

摘要/Abstract

摘要：

目的探讨心力衰竭患者血浆可溶性晚期糖基化终末产物受体(soluble receptor for advanced glycation endproducts,RAGE)浓度变化,分析sRAGE与心功能的关系。方法选择首都医科大学附属北京同仁医院就诊的心力衰竭患者,纽约心脏学会(New York Heart Association,NYHA)心功能分级为Ⅱ~Ⅳ级,同期住院非心力衰竭患者为对照组,用酶联免疫吸附测定法方法定量检测血浆sRAGE浓度,对比分析各组间血浆sRAGE浓度的差异。结果血浆sRAGE浓度在对照组为(0.562±0.473)ng/mL,心力衰竭组为(0.844±0.705)ng/mL,2组间比较差异有统计学意义(P<0.01)。血浆sRAGE浓度在NYHAⅡ级组为(0.680±0.506)ng/mL、NYHAⅢ级组(0.844±0.646)ng/mL、NYHAⅣ级组(91.077±0.910)ng/mL。各组间比较差异有统计学意义(P<0.05)。结论心力衰竭患者血浆sRAGE水平升高,且与心力衰竭的严重程度相关。

关键词: 心力衰竭, 可溶性晚期糖基化终末产物受体, 严重程度

Abstract:

Objective To investigate the level of soluble receptor for advanced glycation endproducts(sRAGE) in patients with heart failure, to analyze the relationship between sRAGE and heart function. Methods Select 100 patients with heart failure treated in our hospital(NYHA Ⅱ-Ⅳ), at the same time collect 50 cases hospitalized without heart failure, record general condition, and use the ELISA method to detect the levels of plasma sRAGE, applied SPSS 16.0 software to carry on statistical analysis. Results The plasma sRAGE level was increased in patients with heart failure than the control group, showing a significant difference(P<0.01). Plasma sRAGE level in the control group was(0.562±0.473)ng/mL, in the heart failure group was(0.844±0.705)ng/mL. With the cardiac function classification increased, plasma sRAGE level was elevated also, the control group was(0.562±0.473)ng/mL, NYHAⅡ level group was(0.680±0.506)ng/mL, NYHAⅢ level group was(0.844±0.646)ng/mL, NYHAⅣ level was(1.077±0.910)ng/mL. there is a significant difference(P=0.004). The plasma level of sRAGE had negative correlation with LVEF in patients with heart failure. Conclusion The plasma level of sRAGE was elevated in patients with heart failure, the level of plasma sRAGE and severity degree of heart failure present a associated relationship, with NYHA heart function classification increased, the plasma sRAGE level was elevated too.

Key words: heart failure, soluble receptor for advanced glycation endproducts, severity level

中图分类号:

郭新颖, 郭彩霞, 杜凤和, 陈步星. 心力衰竭患者血浆可溶性晚期糖基化终末产物受体(sRAGE)变化与心功能的关系[J]. 首都医科大学学报, 2014, 35(6): 805-808.

Guo Xinying, Guo Caixia, Du Fenghe, Chen Buxing. Relationship between plasma sRAGE and heart function in patients with heart failure[J]. Journal of Capital Medical University, 2014, 35(6): 805-808.

参考文献

[1] Bierhaus A, Humpert P M, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products[J]. J Mol Med, 2005,83(11):876-886.
[2] Sakurai S, Yamamoto Y, Tamei H, et al. Development of ELISA for sRAGE and its application to type 1 diabetic patients[J]. Diabetes Res Clin Pract, 2006,73(2):158-165.
[3] Raucci A, Cugusi S, Antonelli A, et al. A soluble form of the receptor for advanced glycation end products(RAGE) is produced by proteolytic cleavage of the membrane bound form by the sheddase a disintegrin and metalloprotease 10(ADAM10)[J]. FASEB J, 2008,22(10):3716-3727.
[4] Basta G, Sironi A M, Lazzerini G, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein[J]. J Clin Endocrinol Metab, 2006,91(11):4628-4634.
[5] 邵亚辉,许顶立.糖基化终极产物对心血管系统的损伤作用及干预措施[J].中国分子心脏病学杂志,2004,4(4):253-256.
[6] Petrova R, Yamamoto Y, Muraki K, et al. Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes[J]. J Mol Cell Cardiol, 2002,34(10):1425-1431.
[7] Raposeiras-Roubín S, Rodiño-Janeiro B K, Grigorian-Shamagian L, et al. Relation of soluble receptor for advanced glycation end products to predict mortality in patients with chronic heart failure independently of Seattle Heart Failure Score[J]. Am J Cardiol, 2011,107(6):938-944.
[8] Polyakova V, Hein s, Kostin S, et al. Matrixmetalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression[J]. J Am Coil Cardiol, 2004,44(8):1609-1618.
[9] Mahajan N, Dhawan V. Receptor for advanced glycation end products(RAGE) in vascular and inflammatory diseases[J]. Int J Cardiol, 2013,168(3):1788-1794.
[10] Devangelio E, Santilli F, Formoso G, et al. Soluble RAGE in type 2 diabetes: association with oxidative stress[J]. Free Radic Biol Med, 2007,43(4):511-518.
[11] Aleshin A, Ananthakrishnan R, Li Q, et al. RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model[J]. Am J Physiol Heart Circ Physiol, 2008,294(4):H1823-H1832.
[12] Norata G D, Garlaschelli K, Grigore L, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population[J]. Nutr Metab Cardiovasc Dis, 2009,19(2):129-134.
[13] Nakamura K, Yamagishi S, Adachi H, et al. Serum levels of soluble form of receptor for advanced glycation end products(sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes[J]. Microvasc Res, 2008,76(1):52-56.
[14] Katakami N, Matsuhisa M, Kaneto H, et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes[J]. Atherosclerosis, 2009,204(1):288-292.
[15] 陈建康,朱鹏立,杨津,等.吡哆胺和替米沙坦对血管紧张素Ⅱ诱导的大鼠心肌细胞氧化应激的影响[J].中国医科大学学报,2012,41(7):622-625.
[16] 张敏,郭彩霞,曾翔俊,等.sRAGE对缺氧/复氧心肌细胞氧化应激的影响[J].首都医科大学学报,2012,33(4):73-78.
[17] 董洪武,郭彩霞,等.缺血/再灌注损伤对大鼠心肌内源性可溶性糖基化终末产物受体分泌的影响[J].首都医科大学学报,2011,32(5):640-644.

心力衰竭患者血浆可溶性晚期糖基化终末产物受体(sRAGE)变化与心功能的关系

Relationship between plasma sRAGE and heart function in patients with heart failure

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	贾艳红, 郭芳, 武晓圆, 李文辉. 儿童肺炎支原体诱导的皮疹和黏膜炎临床特征分析[J]. 首都医科大学学报, 2023, 44(1): 131-136.
[2]	夏勇, 张建卿, 王少霞, 陈丹, 姬建民. 沙库巴曲缬沙坦联合琥珀酸美托洛尔缓释片治疗冠状动脉粥样硬化性心脏病并慢性心力衰竭的效果观察[J]. 首都医科大学学报, 2020, 41(1): 113-118.
[3]	杨敬, 华琦, 李静, 谭静. 急性心力衰竭住院患者的药物治疗分析——多中心现况调查[J]. 首都医科大学学报, 2015, 36(3): 410-413.
[4]	杨伟, 何婧瑜, 王艳玲, 谭静, 范振兴, 华琦. 乌拉地尔与硝酸甘油注射液在老年高血压合并糖尿病患者发作急性心力衰竭的临床有效性与安全性[J]. 首都医科大学学报, 2015, 36(1): 67-72.
[5]	蒋志丽, 李艳芳, 曹芳芳, 刘飞, 白雪源, 吕杨. 心力衰竭大鼠肺脏α_1A及β₁、β₂肾上腺素受体表达的改变[J]. 首都医科大学学报, 2013, 34(1): 140-143.
[6]	王建龙;李海涛;苏丕雄;顾松;刘岩;张希涛;颜钧;安向光;高杰;辛悦;蔡军. 慢性心力衰竭患者全基因组的甲基化改变[J]. 首都医科大学学报, 2012, 33(4): 427-431.
[7]	刘飞;李艳芳;曹芳芳;张玲姬;白雪源;吕杨. 麝香保心丸对心力衰竭大鼠肾脏血管紧张素Ⅱ受体各亚型表达的影响[J]. 首都医科大学学报, 2012, 33(1): 99-102.
[8]	曹芳芳;李艳芳;刘飞;白雪源;吕杨. 麝香保心丸对心肌梗死后心力衰竭大鼠心脏α₁及β肾上腺素能受体表达的影响[J]. 首都医科大学学报, 2010, 31(6): 777-783.
[9]	马力;刘杰;初楠;杨进刚;史旭波;王雅杰;李田昌;胡大一. 心力衰竭模型大鼠心脏肥厚指标与心功能的关系研究[J]. 首都医科大学学报, 2010, 31(5): 596-599.
[10]	王青;孙晓勤;杨明. 贫血和慢性肾脏病对住院充血性心力衰竭患者的影响[J]. 首都医科大学学报, 2007, 28(5): 620-623.
[11]	陈菲;郑亚安. B型利钠肽在心力衰竭诊断与鉴别诊断中的作用及其与心脏超声检查的比较[J]. 首都医科大学学报, 2007, 28(4): 454-456.
[12]	马力;刘杰;初楠;史旭波;杨进刚;李田昌;胡大一. 用运动试验评价心力衰竭模型大鼠心功能[J]. 首都医科大学学报, 2007, 28(3): 350-354.
[13]	罗巍;吴尊友;卫晓丽;贾伟;张群财;李亮亮;颜鸿. 美沙酮维持治疗结果的影响因素研究[J]. 首都医科大学学报, 2007, 28(3): 373-377.
[14]	田海皊;李莉;倪如旸;许毓申. 慢性心力衰竭和睡眠呼吸暂停的相关性研究[J]. 首都医科大学学报, 2006, 27(5): 663-665.
[15]	陈瑾;张麟;杨新春;吴雅峰;李静;李延辉. 应用卡维地洛、比索洛尔和常规方法治疗慢性心力衰竭临床疗效比较[J]. 首都医科大学学报, 2006, 27(2): 229-232.